Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Singlomics
company
About
Singlomics uses single-cell sequencing technology for antibody drug discovery.
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- ¥300M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2020
- Operating Status
- Active
Singlomics uses single-cell sequencing technology to develop antibody drugs for the treatment of infectious diseases and cancers.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
¥300M
Singlomics has raised a total of
¥300M
in funding over 2 rounds. Their latest funding was raised on
Feb 2, 2022 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 2, 2022 | Series B | ¥300M | 3 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
3
Singlomics is funded by 3 investors.
JIANYI CAPITAL
and Witruth Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series B |
Witruth Capital
|
— | Series B |
|
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
